General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews

The growing demand for improved pain treatments together with expanding legalization of, and access to, cannabinoids, cannabis, and cannabis-based medicines has intensified the focus on risk–benefit considerations in pain management. Given limited harms data from analgesic clinical trials, we conducted an overview of systematic reviews focused on all harms possibly relevant to patients receiving cannabinoids for pain management. This PROSPERO-registered, PRISMA-compliant systematic overview identified 79 reviews, encompassing over 2200 individual reports about psychiatric and psychosocial harms, cognitive/behavioral effects, motor vehicle accidents, cardiovascular, respiratory, cancer-related, maternal/fetal, and general harms. Reviews, and their included studies, were of variable quality. Available evidence suggests variable associations between cannabis exposure (ranging from monthly to daily use based largely on self-report) and psychosis, motor vehicle accidents, respiratory problems, and other harms. Most evidence comes from settings other than that of pain management (eg, nonmedicinal and experimental) but does signal a need for caution and more robust harms evaluation in future studies. Given partial overlap between patients receiving cannabinoids for pain management and individuals using cannabinoids for other reasons, lessons from the crisis of oversupply and overuse of opioids in some parts of the world emphasize the need to broadly consider harms evidence from real-world settings. The advancement of research on cannabinoid harms will serve to guide optimal approaches to the use of cannabinoids for pain management. In the meantime, this evidence should be carefully examined when making risk–benefit considerations about the use of cannabinoids, cannabis, and cannabis-based medicine for chronic pain.

Click here to read the full article: https://journals.lww.com/pain/Fulltext/2021/07001/General_risks_of_harm_with_cannabinoids,_cannabis,.7.aspx

About IASP
The International Association on the Study of Pain (IASP) is the leading global organization supporting the study and practice of pain and pain relief. IASP brings together scientists, clinicians, health care providers, and policymakers from around the world in pursuit of their mission to bring relief to those who are in pain.

Like this article?

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on Linkdin
Share on pinterest
Share on Pinterest

Leave a comment

Related Posts

IASIC Speaker Series Presents Cannabis and the Opioid Epidemic

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Is Marijuana a Rite of Passage?

Listen to Dr. Robert DuPont’s discussion on High Truths on Drugs and Addiction, Episode # 13. Is marijuana a rite of passage? Is drug use, like sex, inevitable in teens and young adults? Listen to Dr. Robert DuPont’s discussion on High Truths on Drugs and Addiction, Episode # 13. Dr. Dupont is an IASIC physician

Some CA Pharmacies Now Including Info on Dangerous Interactions with THC and CBD

The use of marijuana can, at times, be confusing for the general public because it is legal for adults in California. The San Diego Marijuana Prevention Initiative has joined with 17 local pharmacies in San Diego County to include information about possible drug interactions with marijuana use when customers pick up their prescriptions. Information, provided

IASIC Speaker Series Presents Cannabis in Neurology

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Michigan officials have ‘no comment’ on how contaminated marijuana made it to store shelves

Michigan’s Marijuana Regulatory Agency (MRA) recently issued a health and safety advisory bulletin due to a voluntary marijuana product recall. Several batches of marijuana were run through the mechanical trimmer of Michigan Medical Marijuana, LLC (AU-G-B-000128) DBA Glo prior to retesting for microbial failures. The mechanical trimmer was contaminated with banned chemical residues Bifenthrin and

Scroll to Top